>> Alexion is has a MAB aimed at reducing the inflammatory response to CABG… They did a study on the MAB vs placebo and found no improvement in cognitive impairment… Anyone here think PARS has a shot at this indication? <<
The larger question is whether this indication is worth pursuing. If cardiac surgeons continue their move toward more frequent use of off-pump CABG (which presumably causes no cognitive impairment that needs prevention or reversal), a drug approved for the cognitive impairment from on-pump CABG may be superfluous.
Clinical outcomes of on-pump vs off-pump CABG are being extensively studied. For instance:
Market Data 
Markets 
AI
